Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 15/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22577502 | 0.91 | TYMP (0.46) | TYMPNT5ETAS1R3TAS1R1IMPDH2 | |
| SCHEMBL22577548 | 0.90 | TYMP (0.66) | TYMPADORA1IMPDH2IMPDH1 | |
| SCHEMBL22577600 | 0.88 | TYMP (0.44) | TYMPNT5E | |
| SCHEMBL25808153 | 0.81 | IMPDH2 (0.35) | NT5ETAS1R3TAS1R1ADORA1IMPDH2 | |
| SCHEMBL22577531 | 0.77 | TYMP (0.48) | TYMPADORA1 | |
| SCHEMBL22034224 | 0.76 | TYMP (0.55) | TYMPADORA1 | |
| SCHEMBL22033791 | 0.76 | TYMP (0.55) | TYMPADORA1 | |
| SCHEMBL17223100 | 0.74 | TYMP (0.64) | TYMPNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL18042134 | 0.74 | TYMP (0.68) | TYMPNT5ETAS1R3TAS1R1 | |
| SCHEMBL16702978 | 0.74 | TYMP (0.68) | TYMPNT5ETAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| EP-3727401-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | TYMP 2186/4885NT5E 1544/4885TAS1R3 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.